Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy

Ryuichi Watanabe, Nobuyuki Fujita, Satoshi Takeda, Yuiko Sato, Tami Kobayashi, Mayu Morita, Takatsugu Oike, Kana Miyamoto, Yoshihiro Matsumoto, Morio Matsumoto, Masaya Nakamura, Takeshi Miyamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Both bone and muscle volume is concomitantly reduced under immobilization conditions; however, no single drug is currently available to block these outcomes simultaneously. Bisphosphonates are utilized clinically to inhibit osteoclast-dependent bone resorption, but their effects on muscle are largely unknown. Here we show that skeletal muscle is a direct target of the bisphosphonate ibandronate (IBN) and that reduced muscle volume and induction of Atrogin-1 and MuRF1, both atrogenes, are significantly inhibited by IBN administration in vivo using a mouse model of muscle atrophy. IBN treatment also significantly blocked immobilization-induced bone loss in vivo. We also report that expression of Atrogin-1 and MuRF1 and accumulation of Smad2/3 proteins, which are upstream of atrogines, occurred following serum starvation of myogenic C2C12 cells in vitro, effects significantly inhibited by IBN treatment. Interestingly, IBN effects on C2C12 cells were abrogated by MG132, an ubiquitin/proteasome inhibitor, suggesting that IBN functions via the ubiquitin-proteasome system. Our findings lend new insight into the role of IBN in preventing muscle atrophy.

Original languageEnglish
Pages (from-to)662-668
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume480
Issue number4
DOIs
Publication statusPublished - 2016 Nov 25

Fingerprint

Muscular Atrophy
Immobilization
Muscle
Bone
Bone and Bones
Diphosphonates
Ubiquitin
Muscles
Smad2 Protein
Proteasome Inhibitors
Osteoclasts
Proteasome Endopeptidase Complex
Bone Resorption
Starvation
ibandronic acid
Skeletal Muscle
Serum
Pharmaceutical Preparations

Keywords

  • Bisphosphonate
  • Bone loss
  • Ibandronate
  • Immobilization
  • Muscle atrophy
  • Osteoclast

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Watanabe, R., Fujita, N., Takeda, S., Sato, Y., Kobayashi, T., Morita, M., ... Miyamoto, T. (2016). Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy. Biochemical and Biophysical Research Communications, 480(4), 662-668. https://doi.org/10.1016/j.bbrc.2016.10.112

Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy. / Watanabe, Ryuichi; Fujita, Nobuyuki; Takeda, Satoshi; Sato, Yuiko; Kobayashi, Tami; Morita, Mayu; Oike, Takatsugu; Miyamoto, Kana; Matsumoto, Yoshihiro; Matsumoto, Morio; Nakamura, Masaya; Miyamoto, Takeshi.

In: Biochemical and Biophysical Research Communications, Vol. 480, No. 4, 25.11.2016, p. 662-668.

Research output: Contribution to journalArticle

Watanabe, R, Fujita, N, Takeda, S, Sato, Y, Kobayashi, T, Morita, M, Oike, T, Miyamoto, K, Matsumoto, Y, Matsumoto, M, Nakamura, M & Miyamoto, T 2016, 'Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy', Biochemical and Biophysical Research Communications, vol. 480, no. 4, pp. 662-668. https://doi.org/10.1016/j.bbrc.2016.10.112
Watanabe, Ryuichi ; Fujita, Nobuyuki ; Takeda, Satoshi ; Sato, Yuiko ; Kobayashi, Tami ; Morita, Mayu ; Oike, Takatsugu ; Miyamoto, Kana ; Matsumoto, Yoshihiro ; Matsumoto, Morio ; Nakamura, Masaya ; Miyamoto, Takeshi. / Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 480, No. 4. pp. 662-668.
@article{04720c6a36ab4c8496d9df83c1c36425,
title = "Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy",
abstract = "Both bone and muscle volume is concomitantly reduced under immobilization conditions; however, no single drug is currently available to block these outcomes simultaneously. Bisphosphonates are utilized clinically to inhibit osteoclast-dependent bone resorption, but their effects on muscle are largely unknown. Here we show that skeletal muscle is a direct target of the bisphosphonate ibandronate (IBN) and that reduced muscle volume and induction of Atrogin-1 and MuRF1, both atrogenes, are significantly inhibited by IBN administration in vivo using a mouse model of muscle atrophy. IBN treatment also significantly blocked immobilization-induced bone loss in vivo. We also report that expression of Atrogin-1 and MuRF1 and accumulation of Smad2/3 proteins, which are upstream of atrogines, occurred following serum starvation of myogenic C2C12 cells in vitro, effects significantly inhibited by IBN treatment. Interestingly, IBN effects on C2C12 cells were abrogated by MG132, an ubiquitin/proteasome inhibitor, suggesting that IBN functions via the ubiquitin-proteasome system. Our findings lend new insight into the role of IBN in preventing muscle atrophy.",
keywords = "Bisphosphonate, Bone loss, Ibandronate, Immobilization, Muscle atrophy, Osteoclast",
author = "Ryuichi Watanabe and Nobuyuki Fujita and Satoshi Takeda and Yuiko Sato and Tami Kobayashi and Mayu Morita and Takatsugu Oike and Kana Miyamoto and Yoshihiro Matsumoto and Morio Matsumoto and Masaya Nakamura and Takeshi Miyamoto",
year = "2016",
month = "11",
day = "25",
doi = "10.1016/j.bbrc.2016.10.112",
language = "English",
volume = "480",
pages = "662--668",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy

AU - Watanabe, Ryuichi

AU - Fujita, Nobuyuki

AU - Takeda, Satoshi

AU - Sato, Yuiko

AU - Kobayashi, Tami

AU - Morita, Mayu

AU - Oike, Takatsugu

AU - Miyamoto, Kana

AU - Matsumoto, Yoshihiro

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Miyamoto, Takeshi

PY - 2016/11/25

Y1 - 2016/11/25

N2 - Both bone and muscle volume is concomitantly reduced under immobilization conditions; however, no single drug is currently available to block these outcomes simultaneously. Bisphosphonates are utilized clinically to inhibit osteoclast-dependent bone resorption, but their effects on muscle are largely unknown. Here we show that skeletal muscle is a direct target of the bisphosphonate ibandronate (IBN) and that reduced muscle volume and induction of Atrogin-1 and MuRF1, both atrogenes, are significantly inhibited by IBN administration in vivo using a mouse model of muscle atrophy. IBN treatment also significantly blocked immobilization-induced bone loss in vivo. We also report that expression of Atrogin-1 and MuRF1 and accumulation of Smad2/3 proteins, which are upstream of atrogines, occurred following serum starvation of myogenic C2C12 cells in vitro, effects significantly inhibited by IBN treatment. Interestingly, IBN effects on C2C12 cells were abrogated by MG132, an ubiquitin/proteasome inhibitor, suggesting that IBN functions via the ubiquitin-proteasome system. Our findings lend new insight into the role of IBN in preventing muscle atrophy.

AB - Both bone and muscle volume is concomitantly reduced under immobilization conditions; however, no single drug is currently available to block these outcomes simultaneously. Bisphosphonates are utilized clinically to inhibit osteoclast-dependent bone resorption, but their effects on muscle are largely unknown. Here we show that skeletal muscle is a direct target of the bisphosphonate ibandronate (IBN) and that reduced muscle volume and induction of Atrogin-1 and MuRF1, both atrogenes, are significantly inhibited by IBN administration in vivo using a mouse model of muscle atrophy. IBN treatment also significantly blocked immobilization-induced bone loss in vivo. We also report that expression of Atrogin-1 and MuRF1 and accumulation of Smad2/3 proteins, which are upstream of atrogines, occurred following serum starvation of myogenic C2C12 cells in vitro, effects significantly inhibited by IBN treatment. Interestingly, IBN effects on C2C12 cells were abrogated by MG132, an ubiquitin/proteasome inhibitor, suggesting that IBN functions via the ubiquitin-proteasome system. Our findings lend new insight into the role of IBN in preventing muscle atrophy.

KW - Bisphosphonate

KW - Bone loss

KW - Ibandronate

KW - Immobilization

KW - Muscle atrophy

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=84994572052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994572052&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.10.112

DO - 10.1016/j.bbrc.2016.10.112

M3 - Article

C2 - 27983979

AN - SCOPUS:84994572052

VL - 480

SP - 662

EP - 668

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -